Subjects aged 18 to 80 years old
Overweight or obesity (BMI =25 kg/m2)
Previous diagnosis of type 2 diabetes, fulfilling at least one of the following criteria: 1) current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level > 6.5 %
Clinical diagnosis of diabetic nephropathy, with a urinary albumin/creatinine ratio >30 mg/g and an estimated glomerular filtration rate more than 20 ml/min per 1.73 m2.
Treatment with stable doses of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or anti-aldosterone agents in the last four weeks.

NCT02816762_inc_T1
Value
18 to 80 years old
NCT02816762_inc_T2
Person
aged
NCT02816762_inc_T3
Condition
obesity
NCT02816762_inc_T4
Measurement
BMI
NCT02816762_inc_T5
Value
=25 kg/m2
NCT02816762_inc_T6
Condition
Overweight
NCT02816762_inc_T7
Scope
Overweight or obesity
NCT02816762_inc_T8
Condition
type 2 diabetes
NCT02816762_inc_T9
Multiplier
at least one
NCT02816762_inc_T10
Temporal
Previous
NCT02816762_inc_T11
Temporal
current
NCT02816762_inc_T12
Drug
oral antidiabetic drugs
NCT02816762_inc_T13
Drug
insulin
NCT02816762_inc_T14
Scope
oral antidiabetic drugs and/or insulin
NCT02816762_inc_T15
Measurement
fasting glucose
NCT02816762_inc_T16
Value
above 126 mg/dl
NCT02816762_inc_T17
Multiplier
on at least 2 occasions
NCT02816762_inc_T18
Measurement
blood glucose level
NCT02816762_inc_T19
Value
equal to or more than 200 mg/dl
NCT02816762_inc_T20
Temporal
at 2 hours after an oral glucose tolerance test
NCT02816762_inc_T21
Reference_point
an oral glucose tolerance test
NCT02816762_inc_T22
Procedure
oral glucose tolerance test
NCT02816762_inc_T23
Measurement
glycated hemoglobin (HbA1c) level
NCT02816762_inc_T24
Value
> 6.5 %
NCT02816762_inc_T25
Scope
current treatment with oral antidiabetic drugs and/or insulin; 2) a fasting glucose value above 126 mg/dl on at least 2 occasions; 3) blood glucose level at 2 hours after an oral glucose tolerance test is equal to or more than 200 mg/dl; or 4) a glycated hemoglobin (HbA1c) level > 6.5 %
NCT02816762_inc_T26
Condition
diabetic nephropathy
NCT02816762_inc_T27
Measurement
urinary albumin/creatinine ratio
NCT02816762_inc_T28
Value
>30 mg/g
NCT02816762_inc_T29
Measurement
estimated glomerular filtration rate
NCT02816762_inc_T30
Value
more than 20 ml/min per 1.73 m2
NCT02816762_inc_T31
Drug
angiotensin-converting enzyme inhibitors
NCT02816762_inc_T32
Multiplier
stable doses
NCT02816762_inc_T33
Drug
angiotensin II receptor blockers
NCT02816762_inc_T34
Drug
anti-aldosterone agents
NCT02816762_inc_T35
Temporal
in the last four weeks
NCT02816762_inc_T36
Scope
angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or anti-aldosterone agents